Bonus Presentations

Hypertension is widespread in the United States — and strikingly, 80% to 85% of people with hypertension also have hypercortisolism (Cushing’s Syndrome). Chronically elevated, untreated cortisol not only worsens cardiometabolic risk factors such as glucose intolerance, dyslipidemia, and abdominal obesity, but also profoundly diminishes quality of life. When hypercortisolism coexists with hypertension that remains uncontrolled despite optimal therapy and multiple medications, the likelihood of heart attack, stroke, and other serious complications rises substantially — demanding timely, intensive intervention. Join us for this symposium at the Heart of Cardiology, where experts will examine the clinical connection between Cushing’s Syndrome and resistant hypertension, outline practical screening and diagnostic strategies, and review both established and emerging treatment options.

Persistent gaps in the management of hypercholesterolemia leave many patients at continued risk for atherosclerotic cardiovascular disease (ASCVD), despite guideline-directed use of statins alone or in combination with other low-density lipoprotein cholesterol LDL-C–lowering therapies. Evidence shows that clinicians, including cardiologists and primary care physicians, often lack up-to-date knowledge of the evolving non-statin landscape—particularly the mechanism, clinical trial data, and appropriate integration of CETP inhibitors for patients who do not achieve or maintain recommended LDL-C goals. This continuing medical education activity is designed to close these gaps through an immersive learning experience led by key experts. During a dedicated symposium, faculty will guide learners through two realistic patient cases, prompting interactive responses and providing expert discussion to reinforce evidence-based decision-making for patients with ASCVD and high cardiovascular risk.

Join our expert panel for a dynamic CME symposium focusing on timely clinical updates on the rapidly advancing landscape of familial chylomicronemia syndrome (FCS) and the broader context of severe hypertriglyceridemia (sHTG). Faculty will break down distinctions between antisense oligonucleotide (ASO) and small interfering RNA (siRNA) apolipoprotein C-III (APOC-III)-targeting therapies, highlight key red flags for early FCS recognition, and translate emerging evidence into practical strategies to optimize triglyceride lowering and reduce pancreatitis risk. A simulated “live lipid clinic” will model real-world encounters, emphasizing patient-centered decision-making and multidisciplinary care to support better outcomes. Register now!

Are you recognizing and treating transthyretin amyloid cardiomyopathy (ATTR-CM)? This dynamic symposium will sharpen your skills to identify patients early, implement disease-targeted therapies, and monitor patients with ATTR-CM over time. Learn to spot multisystem red flags and at-risk populations and apply practical diagnostic pathways (imaging, biomarkers, and genetic testing) to distinguish hereditary from wild-type disease. Our experts will review pivotal clinical trial evidence for currently available therapies and discuss tactics to improve interprofessional collaboration and multidisciplinary care. Commentary from a patient living with ATTR-CM will bring lived experience to clinical decision-making and serve as a foundation for faculty discussion. Attendees will walk away with the tools they need to elevate their practice and optimize outcomes for their patients.

Join us for a focused 30-minute live symposium on optimal management of fluid overload in outpatient heart failure (HF) and chronic kidney disease (CKD) management. First, learn to recognize early congestion, optimize diuretic therapy, and incorporate novel options to safely manage fluid overload and avert hospital admissions. Second, gain clarity on interdisciplinary roles to create coordinated workflows for risk assessment, therapeutic decision-making, medication adherence, and patient education. Through case-based insights and actionable tools, participants will leave equipped to apply practical, team-based strategies that integrate current standards and emerging therapies to improve patient outcomes and reduce avoidable hospitalizations.